TACE Combined with Apatinib is Safe and Effective for the treatment of BCLC Stage C Hepatocellular Carcinoma

Transcatheter arterial chemoembolization (TACE) combined with apatinib (TACE-apatinib) prolonged time to progression (TTP) and overall survival (OS) compared to TACE-alone for Barcelona Clinic Liver Cancer (BCLC) stage C HCC, according to a study published in BMC Cancer.

This retrospective study reviewed 80 consecutive patients with BCLC stage C HCC whose initial treatment consisted of TACE-apatinib or TACE-alone. Clinical and laboratory outcomes, tumor response, TTP, OS, adverse events, and imaging findings at 1 and 3 months after TACE were compared between the groups.

In the TACE-apatinib group, overall response rate was 66.7% at 1 month and 39.6% at 3 months after treatment (P = 0.020) compared with 45.8% at 1 month and 17.6%, at 3 months after treatment (P = 0.021). The median TTP was 6.3 months in the TACE-apatinib group and 3.5 months in the TACE-alone group (P = 0.002). Overall survival was 13.0 months in the TACE-apatinib group and 9.9 months in the TACE-alone group (P = 0.041).

The TACE-apatinib group experienced more side effects, such as hypertension, hand-foot syndrome, oral ulcers, proteinuria, and diarrhea, than in TACE-alone group (P < 0.05).

The authors concluded that, “compared to TACE-alone treatment, TACE-apatinib increased the TTP, OS, and tumor-response rate at 1 and 3 months after treatment of BCLC stage C HCC without any significant increase in severe adverse events.

 

--Kelsey Moroz

 

Reference

Chen S, Yu W, Zhang K, Liu W. Comparison of the efficacy and safety of Transarterial chemoembolization with and without Apatinib for the treatment of BCLC stage C hepatocellular carcinoma. BMC Cancer. 2018;18(1):1131. doi: 10.1186/s12885-018-5081-3.